MEBUATE – Gefitinib Tablet IP 250mg

Description

Mebuate 250

Gefitinib Tablets IP 250 mg – Mebuate 250 mg Tablets

Composition:Gefitinib Tablets IP 250 mg

Dosage Form:  Tablets

Packing: 30 Tablets

Market Authorization: MBA Pharmaceuticals Pvt Ltd

Country of Origin: India

Anti Cancer

Similar to IRESSA

Pharmaceuticals Product

Gefitinib is indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies. The effectiveness of Gefitinib is based on objective response rates. There are non-controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival.